Author: MingMed Biotechnology Co., Ltd.

Posted Date:

May 5, 2026

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026

MingMed Biotechnology Co., Ltd.

May 5, 2026
World’s First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

MingMed Biotechnology Co., Ltd.

April 28, 2026